Bioptimus
Bioptimus, founded by ex-Google DeepMind and Owkin scientists, is building the first universal AI foundation model in biology to drive advancements in scientific research and biotechnological innovation. By employing state-of-the-art AI technologies and accessing unique proprietary data at scale, the company aims to shape the future of scientific research and improve healthcare outcomes globally.
Strategy
Digital Medicine
Status
Live
Website
www.bioptimus.com
Related News
Bioptimus Strengthens Commercial and Scientific Leadership with Key Hires
Bioptimus appoints Julie Gerardi as Chief Commercial Officer
Sofinnova Partners collaborates with NVIDIA to accelerate European life sciences startups
Bioptimus hits $76M funding milestone and prepares to launch groundbreaking foundation model for biology
Bioptimus and Proscia collaborate to accelerate AI innovation in scientific research and drug development for improved patient care
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.